What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Royal Dutch Shell Plc And Antofagasta plc

GlaxoSmithKline plc (LON:GSK), Royal Dutch Shell Plc (LON:RDSB) and Antofagasta (LON:ANTO) are favoured holdings of Merchants Trust plc (LON:MRCH).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Merchants Trust (LSE: MRCH) has delivered 33 consecutive years of dividend increases, and carries a trailing yield of 4.8%. Picking great dividend shares has helped Merchants outperform the FTSE All-Share Index over the past three, five and 10 years.

Heavyweight high yielder GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), biggest holding and top yielder Royal Dutch Shell (LSE: RDSB) and new buy Antofagasta (LSE: ANTO) catch my eye in Merchants’ portfolio.

GlaxoSmithKline

Top FTSE 100 pharmaceuticals firm GlaxoSmithKline still does blockbuster drugs, but Merchants likes the way the company has been consolidating its global leadership positions in vaccines and consumer health, where there are “scale advantages” and “limited risk from generic competition”.

Earlier this month, Glaxo’s management set out its expectations for the reconfigured group. The Board anticipates an earnings decline in the current year at a percentage rate in the high teens, but expects to deliver a compound annual growth rate of mid-to-high single digits over the five-year period 2016-2020.

Management intends to peg the dividend at 80p a share this year and for the next two years. The payout equates to an annual yield of 5.5% for buyers of the shares at the current price of 1,442p. There’ll also be an additional 20p special dividend this year. From 2018, the prospects for dividend increases look good, if management delivers the mid-to-high single digits earnings growth it expects.

Royal Dutch Shell

Like Glaxo, oil supermajor Shell has put a near-term dividend increase on hold. The company has said it intends to pay an unchanged $1.88 a share this year — which may extend to next year, with management guiding on “at least that amount in 2016”.

At current exchange rates, the dollar dividend translates into a sterling payout of 121.3p, giving a yield of 6.1% for buyers of the shares at the current price of 2,000p.

The reason for the temporary halt to a dividend increase is Shell’s agreed £47bn acquisition of BG Group, announced last month. This deal is set to cement Shell’s leading position in the global LNG market and give the company a significant stake in attractive Brazilian assets. That should be good for shareholders’ dividends in the long run, and Merchants Trust is “supportive of the rationale for this deal”.

Antofagasta

Merchants has taken a new position in low-cost copper producer Antofagasta, explaining:

“Copper is an attractive commodity as supply is limited and increasingly expensive to develop whilst demand is broadly spread. Over time supply constraints should lead to a price recovery from depressed levels. The company has one of strongest balance sheets in the sector and is reasonably priced”.

Antofagasta’s dividend yield is a lowly 1.75% in the current subdued environment, but the company has a history of regularly returning excess capital to shareholders via special dividends when business is booming. At the current depressed share price of 775p, the kind of payouts we’ve seen on occasions in the past — and may see again in the future when the copper price recovers — would equate to a yield of 8%-9% during those years.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

With 30% annual returns for a decade, I’m buying this for my Stocks & Shares ISA

Oliver Rodzianko has been looking for a new investment for his Stocks and Shares ISA. Here's one he's decided is…

Read more »

Investing Articles

These were the FTSE 100’s dogs and stars in February

The FTSE 100 limped along last month, but some Footsie shares soared while others slumped. Here are February's winners and…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

This £43bn of passive income is up for grabs today!

As a lover of passive income, I'm always on the lookout for extra cash. The good news is that these…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

Is this my once-in-a-decade chance to buy these 2 beaten-down UK shares before they rocket?

The FTSE 100 has had a bumpy ride but these two UK shares have had it bumpier. Could now be…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

£6k bought me 3,093 shares in this overlooked FTSE passive income stock yielding 9.1% a year

This FTSE 100 dividend stock pays one of the most generous levels of passive income on the index, yet often…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

With a 5.35% yield does it matter if the National Grid share price never rises again?

The National Grid share price will never fly to the stars, but given the regular supply of dividends it offers,…

Read more »

Risk reward ratio / risk management concept
Investing Articles

Here’s why I think the Lloyds share price is undervalued but still not worth me buying

Oliver Rodzianko reckons the Lloyds share price is not appealing enough for him to make a long-term value investment in…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Insiders are buying Rolls-Royce shares! Should I do the same

Two directors have been buying Rolls-Royce shares since the start of the year. Does that mean the rally has further…

Read more »